EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Impact of Pharmacokinetic Gene Polymorphisms on Statin‐Induced Myotoxicity in Thai Patients Treated With Simvastatin

Sayanit Tipnoppanon iD, Sarawut Siwamogsatham, Yongkasem Vorasettakarnkij, Chonlaphat Sukasem, Pajaree Chariyavilaskul iD, Patompong Satapornpong, Natchaya Vanwong iD

Clinical and Translational Science · 2026-04 · 19 (4)

DOI: 10.1111/cts.70528 ↗

At a glance

Journal article in Clinical and Translational Science, published online on 2026-03-20. Written by Sayanit Tipnoppanon and 6 co-authors. Institution: Department of Clinical Chemistry, The Ph.D. Program in Clinical Biochemistry and Molecular Medicine, Faculty of Allied Health Sciences, Chulalongkorn…. Major MEDLINE topics: Simvastatin, Liver-Specific Organic Anion Transporter 1, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Polymorphism, Single Nucleotide. 42 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: This research was financially supported by the Thailand Science Research and Innovation Fund, Chulalongkorn University [grant number HEA663700098], and the 100…, King Chulalongkorn Memorial Hospital.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Statin‐induced myotoxicity (SIM) is a common adverse effect of simvastatin therapy, which can negatively impact patient adherence and treatment outcomes. This study aims to investigate the impacts of pharmacokinetic (PK) gene polymorphisms on SIM in Thai population treated with simvastatin. One hundred forty‐eight Thai participants, including 23 with SIM and 125 tolerant controls were enrolled. The pharmacokinetic genes including, ABCB1, ABCC2, ABCG2, SLCO1B1, SLCO1B3, CYP3A4, and CYP3A5 , were genotyped using MassARRAY System. Significant associations were identified for C allele of SLCO1B1 rs4149056 (c.521T>C) (OR = 1.9; 95% CI: 1.1–3.5; p = 0.02) and T allele of ABCC2 rs717620 (−24C>T) (OR = 2.2; 95% CI = 1.1–4.4; p = 0.02). Haplotype analysis of SLCO1B1 c.521T>C and c.388A>G revealed that the *15 haplotype (c.521C and c.388G) was significantly associated with SIM, with a higher frequency in SIM cases (13.0%) compared to controls (6.0%) (OR 2.8; 95% CI = 1.3–6.0; p < 0.01). Furthermore, the decreased function phenotype of OATP1B1 ( SLCO1B1*1b/*5 or * 1b/*15 ), was associated with SIM compared to normal function phenotype. Notably, patients with the decreased function phenotype using simvastatin 20–40 mg/day had a substanstially increase risk of SIM (OR = 10.0; 95% CI = 1.6–63.4; p = 0.02). These findings highlight the influence of PK gene polymorphisms on SIM risk and support the importance of genotype‐guided simvastatin therapy to minimize adverse effects and improve patient care. Moreover, these also reinforce current CPIC guidelines, which recommend adjusting statins, including simvastatin, therapy based on SLCO1B1 genotype to reduce the risk of myopathy.

Subjects

MeSH terms (MEDLINE)

SimvastatinLiver-Specific Organic Anion Transporter 1Hydroxymethylglutaryl-CoA Reductase InhibitorsPolymorphism, Single NucleotideMyotoxicityPharmacogenomic VariantsHumansFemaleMaleMiddle AgedThailandMultidrug Resistance-Associated Protein 2HaplotypesAdultAgedCase-Control Studies

Author keywords

SLCO1B1OATP1B1pharmacokineticssimvastatinstatin‐induced myotoxicity

Substances

SimvastatinLiver-Specific Organic Anion Transporter 1Hydroxymethylglutaryl-CoA Reductase InhibitorsSLCO1B1 protein, humanMultidrug Resistance-Associated Protein 2ABCC2 protein, human

Authors and institutions

  • Department of Clinical Chemistry, The Ph.D. Program in Clinical Biochemistry and Molecular Medicine, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand.
  • Division of Hospital and Ambulatory Medicine, Department of Medicine, King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Maha Chakri Sirindhorn Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand.
  • Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Chulalongkorn University, Bangkok, Thailand.

ORCID profiles: Sayanit Tipnoppanon, Pajaree Chariyavilaskul, Natchaya Vanwong

Funding

  • This research was financially supported by the Thailand Science Research and Innovation Fund, Chulalongkorn University [grant number HEA663700098], and the 100…
  • King Chulalongkorn Memorial Hospital

Cite

APA

Tipnoppanon, S., Siwamogsatham, S., Vorasettakarnkij, Y., Sukasem, C., Chariyavilaskul, P., Satapornpong, P., & Vanwong, N. (2026). Impact of Pharmacokinetic Gene Polymorphisms on Statin‐Induced Myotoxicity in Thai Patients Treated With Simvastatin. Clinical and Translational Science, 19(4). https://doi.org/10.1111/cts.70528

Vancouver

Tipnoppanon S, Siwamogsatham S, Vorasettakarnkij Y, Sukasem C, Chariyavilaskul P, Satapornpong P, et al. Impact of Pharmacokinetic Gene Polymorphisms on Statin‐Induced Myotoxicity in Thai Patients Treated With Simvastatin. Clinical and Translational Science. 2026;19(4). doi:10.1111/cts.70528

BibTeX
@article{Tipnoppanon2026,
  author = {Tipnoppanon, Sayanit and Siwamogsatham, Sarawut and Vorasettakarnkij, Yongkasem and Sukasem, Chonlaphat and Chariyavilaskul, Pajaree and Satapornpong, Patompong and Vanwong, Natchaya},
  title = {Impact of Pharmacokinetic Gene Polymorphisms on Statin‐Induced Myotoxicity in Thai Patients Treated With Simvastatin},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {4},
  doi = {10.1111/cts.70528}
}
Start for free →